2023 美国风湿病学会 (ACR)/ 美国胸科医师学会 (CHEST) 《系统性自身免疫性风湿病患者间质性肺病治疗指南》。

IF 3.7 2区 医学 Q1 RHEUMATOLOGY Arthritis Care & Research Pub Date : 2024-07-08 DOI:10.1002/acr.25348
Sindhu R. Johnson, Elana J. Bernstein, Marcy B. Bolster, Jonathan H. Chung, Sonye K. Danoff, Michael D. George, Dinesh Khanna, Gordon Guyatt, Reza D. Mirza, Rohit Aggarwal, Aberdeen Allen Jr, Shervin Assassi, Lenore Buckley, Hassan A. Chami, Douglas S. Corwin, Paul F. Dellaripa, Robyn T. Domsic, Tracy J. Doyle, Catherine Marie Falardeau, Tracy M. Frech, Fiona K. Gibbons, Monique Hinchcliff, Cheilonda Johnson, Jeffrey P. Kanne, John S. Kim, Sian Yik Lim, Scott Matson, Zsuzsanna H. McMahan, Samantha J. Merck, Kiana Nesbitt, Mary Beth Scholand, Lee Shapiro, Christine D. Sharkey, Ross Summer, John Varga, Anil Warrier, Sandeep K. Agarwal, Danielle Antin-Ozerkis, Bradford Bemiss, Vaidehi Chowdhary, Jane E. Dematte D'Amico, Robert Hallowell, Alicia M. Hinze, Patil A. Injean, Nikhil Jiwrajka, Elena K. Joerns, Joyce S. Lee, Ashima Makol, Gregory C. McDermott, Jake G. Natalini, Justin M. Oldham, Didem Saygin, Kimberly Showalter Lakin, Namrata Singh, Joshua J. Solomon, Jeffrey A. Sparks, Marat Turgunbaev, Samera Vaseer, Amy Turner, Stacey Uhl, Ilya Ivlev
{"title":"2023 美国风湿病学会 (ACR)/ 美国胸科医师学会 (CHEST) 《系统性自身免疫性风湿病患者间质性肺病治疗指南》。","authors":"Sindhu R. Johnson,&nbsp;Elana J. Bernstein,&nbsp;Marcy B. Bolster,&nbsp;Jonathan H. Chung,&nbsp;Sonye K. Danoff,&nbsp;Michael D. George,&nbsp;Dinesh Khanna,&nbsp;Gordon Guyatt,&nbsp;Reza D. Mirza,&nbsp;Rohit Aggarwal,&nbsp;Aberdeen Allen Jr,&nbsp;Shervin Assassi,&nbsp;Lenore Buckley,&nbsp;Hassan A. Chami,&nbsp;Douglas S. Corwin,&nbsp;Paul F. Dellaripa,&nbsp;Robyn T. Domsic,&nbsp;Tracy J. Doyle,&nbsp;Catherine Marie Falardeau,&nbsp;Tracy M. Frech,&nbsp;Fiona K. Gibbons,&nbsp;Monique Hinchcliff,&nbsp;Cheilonda Johnson,&nbsp;Jeffrey P. Kanne,&nbsp;John S. Kim,&nbsp;Sian Yik Lim,&nbsp;Scott Matson,&nbsp;Zsuzsanna H. McMahan,&nbsp;Samantha J. Merck,&nbsp;Kiana Nesbitt,&nbsp;Mary Beth Scholand,&nbsp;Lee Shapiro,&nbsp;Christine D. Sharkey,&nbsp;Ross Summer,&nbsp;John Varga,&nbsp;Anil Warrier,&nbsp;Sandeep K. Agarwal,&nbsp;Danielle Antin-Ozerkis,&nbsp;Bradford Bemiss,&nbsp;Vaidehi Chowdhary,&nbsp;Jane E. Dematte D'Amico,&nbsp;Robert Hallowell,&nbsp;Alicia M. Hinze,&nbsp;Patil A. Injean,&nbsp;Nikhil Jiwrajka,&nbsp;Elena K. Joerns,&nbsp;Joyce S. Lee,&nbsp;Ashima Makol,&nbsp;Gregory C. McDermott,&nbsp;Jake G. Natalini,&nbsp;Justin M. Oldham,&nbsp;Didem Saygin,&nbsp;Kimberly Showalter Lakin,&nbsp;Namrata Singh,&nbsp;Joshua J. Solomon,&nbsp;Jeffrey A. Sparks,&nbsp;Marat Turgunbaev,&nbsp;Samera Vaseer,&nbsp;Amy Turner,&nbsp;Stacey Uhl,&nbsp;Ilya Ivlev","doi":"10.1002/acr.25348","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.</p>\n </section>\n </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25348","citationCount":"0","resultStr":"{\"title\":\"2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases\",\"authors\":\"Sindhu R. Johnson,&nbsp;Elana J. Bernstein,&nbsp;Marcy B. Bolster,&nbsp;Jonathan H. Chung,&nbsp;Sonye K. Danoff,&nbsp;Michael D. George,&nbsp;Dinesh Khanna,&nbsp;Gordon Guyatt,&nbsp;Reza D. Mirza,&nbsp;Rohit Aggarwal,&nbsp;Aberdeen Allen Jr,&nbsp;Shervin Assassi,&nbsp;Lenore Buckley,&nbsp;Hassan A. Chami,&nbsp;Douglas S. Corwin,&nbsp;Paul F. Dellaripa,&nbsp;Robyn T. Domsic,&nbsp;Tracy J. Doyle,&nbsp;Catherine Marie Falardeau,&nbsp;Tracy M. Frech,&nbsp;Fiona K. Gibbons,&nbsp;Monique Hinchcliff,&nbsp;Cheilonda Johnson,&nbsp;Jeffrey P. Kanne,&nbsp;John S. Kim,&nbsp;Sian Yik Lim,&nbsp;Scott Matson,&nbsp;Zsuzsanna H. McMahan,&nbsp;Samantha J. Merck,&nbsp;Kiana Nesbitt,&nbsp;Mary Beth Scholand,&nbsp;Lee Shapiro,&nbsp;Christine D. Sharkey,&nbsp;Ross Summer,&nbsp;John Varga,&nbsp;Anil Warrier,&nbsp;Sandeep K. Agarwal,&nbsp;Danielle Antin-Ozerkis,&nbsp;Bradford Bemiss,&nbsp;Vaidehi Chowdhary,&nbsp;Jane E. Dematte D'Amico,&nbsp;Robert Hallowell,&nbsp;Alicia M. Hinze,&nbsp;Patil A. Injean,&nbsp;Nikhil Jiwrajka,&nbsp;Elena K. Joerns,&nbsp;Joyce S. Lee,&nbsp;Ashima Makol,&nbsp;Gregory C. McDermott,&nbsp;Jake G. Natalini,&nbsp;Justin M. Oldham,&nbsp;Didem Saygin,&nbsp;Kimberly Showalter Lakin,&nbsp;Namrata Singh,&nbsp;Joshua J. Solomon,&nbsp;Jeffrey A. Sparks,&nbsp;Marat Turgunbaev,&nbsp;Samera Vaseer,&nbsp;Amy Turner,&nbsp;Stacey Uhl,&nbsp;Ilya Ivlev\",\"doi\":\"10.1002/acr.25348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.</p>\\n </section>\\n </div>\",\"PeriodicalId\":8406,\"journal\":{\"name\":\"Arthritis Care & Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25348\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arthritis Care & Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acr.25348\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Care & Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acr.25348","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要我们就系统性自身免疫性风湿病(SARDs)成人患者间质性肺病(ILD)的治疗提供循证建议:方法:我们提出了与临床相关的人群、干预措施、参照物和结果等问题。然后进行了系统的文献综述,并采用建议分级、评估、开发和评价方法对现有证据进行了评级。一个由临床医生和患者组成的小组就建议的方向和力度达成了共识:结果:针对一线 SARD-ILD 治疗、一线 ILD 治疗后 SARD-ILD 进展的治疗以及快速进展性 ILD 的治疗提出了 35 项建议(包括两项强力建议)。强烈建议反对将糖皮质激素用于系统性硬化-ILD 的一线 ILD 治疗和 ILD 进展后的治疗。否则,有条件地推荐糖皮质激素用于所有其他 SARDs 的一线 ILD 治疗:本临床实践指南首次提出了美国风湿病学会和美国胸科医师学会认可的治疗 SARDs 患者 ILD 的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases

Objective

We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs).

Methods

We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations.

Results

Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs.

Conclusion

This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.40
自引率
6.40%
发文量
368
审稿时长
3-6 weeks
期刊介绍: Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the College), is a peer-reviewed publication that publishes original research, review articles, and editorials that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with rheumatic diseases, major topics are evidence-based practice studies, clinical problems, practice guidelines, educational, social, and public health issues, health economics, health care policy, and future trends in rheumatology practice.
期刊最新文献
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Issue Information Area-level socioeconomic status impacts healthcare visit frequency by Australian inflammatory arthritis patients: results from the Australian Rheumatology Association Database. Building the OAChangeMap to improve the service delivery of the New South Wales Osteoarthritis Chronic Care Program: a worked example of using a co-design framework. Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset ANCA-Associated Vasculitis: An ARChiVe registry-cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1